- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02854761
Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The etiology of RRP is associated with local immune suppression at disease-involved sites.
EF-022, a Vitamin D-Binding protein Macrophage Activating Factor, modulates the innate arm of the immune system to alleviate immune suppression. The investigators hypothesize that EF-022 may modulate the immune response in a manner that might slow down or even prevent disease progression.
Adult subjects will be treated weekly with EF-022 for a period of 6 months by either intramuscular or subcutaneous administration.
The primary objective of the study is to evaluate the safety and tolerability of EF-022 administered to adult subjects with recurrent respiratory papillomatosis either IM or SC.
The main response assessment will be performed over the 6 months period by:
- Evaluating lesion size and/or number of disease-involved sites by Coltera-Derkay score
- Assessment of degree of voice disorder using the VHI-10 score
- Symptomatic assessment of dyspnea/stridor
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Myriam Golembo, PhD
- Phone Number: 972-8-9724972
- Email: myriam.golembo@efranat.com
Study Contact Backup
- Name: Uri Yogev
- Phone Number: 972-8-9724972
- Email: uri.yogev@efranat.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with documented diagnosis of recurrent respiratory papillomatosis
- Patients with measurable disease
- Patients presenting at least one of the following severity criteria: Derkay score ≥ 8 , Voice handicap index (VHI) ≥11
- Adult male and female subjects, age of 18 and above (≥18 yrs)
- Patients with documentation on number of debulking procedures done during past 12 months
- Estimated expectancy time for next debulking procedure must be at least 3 months.
- Must be at least 4 weeks (>4 weeks) since last treatment including cytotoxic therapy, biological or immunotherapy, anti-viral therapy, molecularly targeted therapy or steroid treatment.
- Must be at least 2 weeks (>2weeks) since last NSAID treatment.
- Must have adequately recovered (to at least Grade 1 level) from adverse effects of prior therapies.
- Female of child bearing potential must have a negative pregnancy test and must be practicing an effective method of birth control
- Patients or their guardians must sign an informed consent indicating that they are aware of the investigational nature of this study
Exclusion Criteria:
- Patient on concurrent steroids or anti-inflammatory non steroid treatment.
- Active autoimmune disease
- Known major immunodeficiency
- Known to be Positive for HIV, Hepatitis B surface antigen, Hepatitis C antibody
- Have absolute neutrophil counts below 1.5X 10^9/L
- Hemoglobin below 10.0 g/dL
- White blood cell counts below 3.5X10^9/L.
- Granulocytes below 1.5X10^9/L.
- Have Platelets below 100 X 10^9/L
- Abnormal renal function with creatinine above 1.5X the upper limit of normal (ULN)
- Abnormal liver function tests with bilirubin above 1.5X the ULN, AST and ALT above 2.5 X ULN.
- Patients with active cardiovascular disease under continuous treatment
- Patients with associated malignancy currently receiving chemotherapy and/or radiation.
- Female adult patients that are pregnant, nursing or plan to nurse during and up to 12 months of treatment period.
- Subjects receiving another investigational drug.
- Patients with concurrent or history of malignancy within 5 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SC administration
Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
|
|
Experimental: IM administration
Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CTCAE v.4.03 criteria will constitute the primary safety endpoints to be monitored throughout this study
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Virus Diseases
- Infections
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- DNA Virus Infections
- Tumor Virus Infections
- Neoplasms, Squamous Cell
- Recurrence
- Respiratory Tract Infections
- Papillomavirus Infections
- Papilloma
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Vitamin D
Other Study ID Numbers
- CS-102
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Respiratory Papillomatosis
-
National Cancer Institute (NCI)CompletedHuman Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory PapillomatosisUnited States
-
Queen Sirikit National Institute of Child HealthMerck Sharp & Dohme LLCCompletedHuman Papilloma Virus | Recurrent Laryngeal PapillomatosisThailand
-
Centro de Investigación en. Enfermedades Infecciosas...UnknownRecurrent Respiratory PapillomatosisMexico
-
National Institute of Child Health, HungaryMerck Sharp & Dohme LLCUnknownRecurrent Respiratory PapillomatosisHungary
-
Nventa Biopharmaceuticals CorporationCompletedPapilloma | Recurrent Respiratory PapillomatosisUnited States
-
Imagine InstituteRecruitingJuvenile Recurrent Respiratory PapillomatosisFrance
-
Massachusetts Eye and Ear InfirmaryWithdrawnRecurrent Respiratory Papillomatosis
-
Massachusetts General HospitalCompletedRecurrent Respiratory PapillomatosisUnited States
-
National Cancer Institute (NCI)CompletedHuman Papilloma Virus | Recurrent Respiratory Papillomatosis | Laryngeal Papilloma, Recurrent | Respiratory Papillomatosis | Juvenile Laryngeal PapillomaUnited States
-
Massachusetts Eye and Ear InfirmaryRady Children's Hospital, San DiegoCompletedRecurrent Respiratory PapillomatosisUnited States
Clinical Trials on EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
-
Efranat Ltd.Completed
-
Marmara UniversityCompleted